ID: ALA601906

Max Phase: Preclinical

Molecular Formula: C36H48N6O7

Molecular Weight: 676.81

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCOC(=O)N1CCN(C(=O)[C@H](CCC(=O)O)NC(=O)c2cc(N3CCC(C(=O)N4CCCC4)CC3)cc(-c3ccccc3)n2)CC1

Standard InChI:  InChI=1S/C36H48N6O7/c1-2-3-23-49-36(48)42-21-19-41(20-22-42)35(47)29(11-12-32(43)44)38-33(45)31-25-28(24-30(37-31)26-9-5-4-6-10-26)39-17-13-27(14-18-39)34(46)40-15-7-8-16-40/h4-6,9-10,24-25,27,29H,2-3,7-8,11-23H2,1H3,(H,38,45)(H,43,44)/t29-/m0/s1

Standard InChI Key:  VHJZVQVHJHUWNG-LJAQVGFWSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 676.81

Molecular Weight (Monoisotopic): 676.3584

AlogP: 3.63

#Rotatable Bonds: 12

Polar Surface Area: 152.69

Molecular Species: ACID

HBA: 8

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 13

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 4.02

CX Basic pKa: 6.13

CX LogP: 0.97

CX LogD: -0.15

Aromatic Rings: 2

Heavy Atoms: 49

QED Weighted: 0.32

Np Likeness Score: -0.91

References

1. Parlow JJ, Burney MW, Case BL, Girard TJ, Hall KA, Harris PK, Hiebsch RR, Huff RM, Lachance RM, Mischke DA, Rapp SR, Woerndle RS, Ennis MD..  (2010)  Part II: piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.,  20  (4): [PMID:20097563] [10.1016/j.bmcl.2009.12.110]

Source

Source(1):

• Scientific Literature